Novo Nordisk kicks off phase III trial program for new insulin hope
Even though the insulin market is under pressure, Novo Nordisk's faith in its new once-weekly insulin leads the firm to launch a major phase IIIa program for the drug
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Even though drugs like Ozempic and Rybelsus often steal the attention at Novo Nordisk, the firm is also highly occupied with its insulin business.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk's CFO expects US growth boost this year
For subscribers
